News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.
- The Reference ULTRA PLUS Tissue Staining System, with optimized workflow, testing efficiency, and eco-friendly features, enables pathologists to deliver high-quality, time-sensitive results to physicians and patients.
- With laboratory diagnostics involved in more than two-thirds of healthcare decision makingInnovative laboratory solutions that enable accurate and rapid diagnosis are essential for successful treatment.
- About 17 million new cases of cancer are diagnosed each year worldwide and nearly 10 million people die from this disease.1
Basel, June 29, 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the BenchMark ULTRA PLUS System, its brand new advanced tissue staining platform. The system provides fast and accurate test results so clinicians can make timely decisions about a patient’s care pathway.
“With BenchMark ULTRA PLUS, we are excited to offer an advanced tissue staining platform co-developed with laboratory professionals,” said Thomas Schinecker, CEO of Roche Diagnostics. “Waiting for a diagnosis is often one of the most stressful times for patients. This system enables pathologists to provide fast and accurate results that help inform patient treatment options. »
Cancer and other abnormal cells can be characterized by biochemical markers inside the cells. By applying chemical solutions to tissue on glass slides with the BenchMark ULTRA PLUS, a healthcare professional can identify these markers to determine the presence or absence of key factors that fuel unhealthy cells and, in many cases, the type of therapy that could be used to combat them.
The new BenchMark ULTRA PLUS system continues the evolution of the BenchMark series, which has revolutionized cancer diagnosis by fully automating processes that were previously done manually, one slide at a time.
Lab staff will be able to manage their operations more efficiently with simplified software and streamlined productivity and quality control. These improvements can help provide test results more quickly to patients awaiting diagnosis.
The new system features several innovations such as new intuitive software, remote monitoring features, an integrated touch screen for a more optimized user experience, as well as a more environmentally friendly waste management system and product packaging. ‘environment.
The BenchMark ULTRA PLUS system will be available in European Union countries in July 2022 and in the United States and the Asia-Pacific market in September 2022, followed by a global rollout in 2023.
About Reference ULTRA MORE system
The BenchMark ULTRA PLUS system (including hardware, software and assays) builds on the success of the current BenchMark series of advanced IHC/ISH staining platforms. It builds on the proven technology of the BenchMark ULTRA system to deliver an enhanced lab experience. The BenchMark ULTRA PLUS system offers an optimized workflow and flexible solutions, helping the pathology laboratory run its business efficiently and with confidence while selecting the options that best suit their laboratory.
BenchMark ULTRA was the first advanced staining instrument to provide true one-piece flow. BenchMark ULTRA PLUS pushes the boundaries even further with its enhanced VENTANA system software, which improves quality control, inventory management, and overall user experience through its modern architecture. The BenchMark ULTRA PLUS incorporates several additional innovative features based on customer feedback, including remote monitoring with a connected device, new indicator lights, retractable work surface, new sliding drawers (which mitigate entry/ fluid outlet), a new integrated and more environmentally friendly touch screen. Waste-friendly segregation and degradation. Sustainable packaging uses 40% less raw materials and weighs less to reduce the carbon footprint during transport. The system is manufactured using innovative and efficient assembly practices to ensure product quality and delivery.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded drugs, Roche has become the world’s largest biotechnology company and the world leader in in vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics to improve and save the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform the way healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in diagnostics and pharmacy with insights from clinical practice.
In recognition of our efforts to pursue a long-term perspective in everything we do, Roche has been named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indexes for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare with local partners in all the countries where we work.
Genentech, in the United States, is a full member of the Roche group. Roche is the majority shareholder of Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this press release are protected by law.
 World cancer facts and figures, https://www.cancer.org/research/cancer-facts-statistics/global.html
Roche Group Media Relations
Phone: +41 61 688 8888 / email: [email protected]
|Hyears Trees, PhD
Telephone: +41 61 687 41 47
Telephone: +41 61 682 28 31
Phone: +41 79 327 54 74
Telephone: +41 79 771 05 25
|Dr. Barbara von Schnurbein
Telephone: +41 61 687 89 67
Telephone: +41 79 935 81 48